Eugenol and derivatives activity against Mycobacterium tuberculosis, nontuberculous mycobacteria and other bacteria
To evaluate (i) the in vitro activity of eugenol (EUG) and three derivatives against Mycobacterium tuberculosis (Mtb), nontuberculous mycobacteria (NTM) and other bacteria, (ii) the EUG and antituberculosis drugs combinatory effect and (iii) the EUG and its derivatives cytotoxicity. Minimum inhibito...
Gespeichert in:
| Veröffentlicht in: | Future microbiology 2019-03, Vol.14 (4), p.331-344 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 344 |
|---|---|
| container_issue | 4 |
| container_start_page | 331 |
| container_title | Future microbiology |
| container_volume | 14 |
| creator | de Almeida, Aryadne L Caleffi-Ferracioli, Katiany R de L Scodro, Regiane B Baldin, Vanessa P Montaholi, Débora C Spricigo, Luiza F Nakamura-Vasconcelos, Sandra S Hegeto, Laíse A Sampiron, Eloísa G Costacurta, Giovana F Dos S Yamazaki, Diego A F Gauze, Gisele de Siqueira, Vera Ld Cardoso, Rosilene F |
| description | To evaluate (i) the in vitro activity of eugenol (EUG) and three derivatives against Mycobacterium tuberculosis (Mtb), nontuberculous mycobacteria (NTM) and other bacteria, (ii) the EUG and antituberculosis drugs combinatory effect and (iii) the EUG and its derivatives cytotoxicity.
Minimum inhibitory concentration of the compounds were determined by resazurin microtiter or broth microdilution assay and the drug interaction between EUG and antituberculosis drugs by resazurin drug combination microtiter. The cytotoxicity was carried out in macrophages, HeLa and VERO cells. Results: EUG and derivatives displayed activity and synergic effect of EUG combined with rifampicin, isoniazid, ethambutol, and pyrazinamide in Mtb including multidrug-resistant isolates, with more selectivity to bacillus than macrophages, HeLa and VERO cells (selective index from 0.65 to 31.4). EUG derivatives (4-allyl-2-methoxyphenyl acetate, 4-allyl-2-methoxyphenyl benzoate, and 4-allyl-2-methoxyphenyl 4-nitrobenzoate) were more active against nontuberculous mycobacteria than EUG. EUG and derivatives exhibited low activity in other Gram-positive and -negative bacteria.
EUG and its derivatives show activity against Mycobacterium spp. and synergic effect of EUG combined with antituberculosis drugs against Mtb. |
| doi_str_mv | 10.2217/fmb-2018-0333 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2207937368</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2207937368</sourcerecordid><originalsourceid>FETCH-LOGICAL-c321t-54c27a618a7953de8925caca49fc5a88081e77a8fe580b07cfd5bae5d3322a1c3</originalsourceid><addsrcrecordid>eNpd0c1LwzAYBvAgipvTo1cJePFgNR9Lkx5lzA-YeNFzeZums6NtZtIM9t8vcx-Cpze8_Hh4yYPQNSUPjFH5WLVFwghVCeGcn6AhleM0IRmjp8c35QN04f2CEKFoRs_RgBMpZEbTIfLTMDedbTB0JS6Nq1fQ1yvjMeg4636NYQ5153v8vta2iNtoQov7UBinQ2N97e9xZ7vjInjc_lH4Dbb9t3H4sLpEZxU03lzt5wh9PU8_J6_J7OPlbfI0SzRntE_EWDMJKVUgM8FLozImNGgYZ5UWoBRR1EgJqjJCkYJIXZWiACNKzhkDqvkI3e1yl87-BOP7vK29Nk0DnYln5owRmXHJUxXp7T-6sMF18bqoaCqYlFJEleyUdtZ7Z6p86eoW3DqnZOtkHtvIt23k2zaiv9mnhqI15VEfvp9vANU7h_E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216527775</pqid></control><display><type>article</type><title>Eugenol and derivatives activity against Mycobacterium tuberculosis, nontuberculous mycobacteria and other bacteria</title><source>PubMed Central</source><creator>de Almeida, Aryadne L ; Caleffi-Ferracioli, Katiany R ; de L Scodro, Regiane B ; Baldin, Vanessa P ; Montaholi, Débora C ; Spricigo, Luiza F ; Nakamura-Vasconcelos, Sandra S ; Hegeto, Laíse A ; Sampiron, Eloísa G ; Costacurta, Giovana F ; Dos S Yamazaki, Diego A ; F Gauze, Gisele de ; Siqueira, Vera Ld ; Cardoso, Rosilene F</creator><creatorcontrib>de Almeida, Aryadne L ; Caleffi-Ferracioli, Katiany R ; de L Scodro, Regiane B ; Baldin, Vanessa P ; Montaholi, Débora C ; Spricigo, Luiza F ; Nakamura-Vasconcelos, Sandra S ; Hegeto, Laíse A ; Sampiron, Eloísa G ; Costacurta, Giovana F ; Dos S Yamazaki, Diego A ; F Gauze, Gisele de ; Siqueira, Vera Ld ; Cardoso, Rosilene F</creatorcontrib><description>To evaluate (i) the in vitro activity of eugenol (EUG) and three derivatives against Mycobacterium tuberculosis (Mtb), nontuberculous mycobacteria (NTM) and other bacteria, (ii) the EUG and antituberculosis drugs combinatory effect and (iii) the EUG and its derivatives cytotoxicity.
Minimum inhibitory concentration of the compounds were determined by resazurin microtiter or broth microdilution assay and the drug interaction between EUG and antituberculosis drugs by resazurin drug combination microtiter. The cytotoxicity was carried out in macrophages, HeLa and VERO cells. Results: EUG and derivatives displayed activity and synergic effect of EUG combined with rifampicin, isoniazid, ethambutol, and pyrazinamide in Mtb including multidrug-resistant isolates, with more selectivity to bacillus than macrophages, HeLa and VERO cells (selective index from 0.65 to 31.4). EUG derivatives (4-allyl-2-methoxyphenyl acetate, 4-allyl-2-methoxyphenyl benzoate, and 4-allyl-2-methoxyphenyl 4-nitrobenzoate) were more active against nontuberculous mycobacteria than EUG. EUG and derivatives exhibited low activity in other Gram-positive and -negative bacteria.
EUG and its derivatives show activity against Mycobacterium spp. and synergic effect of EUG combined with antituberculosis drugs against Mtb.</description><identifier>ISSN: 1746-0913</identifier><identifier>EISSN: 1746-0921</identifier><identifier>DOI: 10.2217/fmb-2018-0333</identifier><identifier>PMID: 30757916</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Acetic acid ; Antimicrobial agents ; Bacteria ; Cytotoxicity ; Drug interaction ; Drug interactions ; Drugs ; Ethambutol ; Eugenol ; Gram-negative bacteria ; HIV ; Human immunodeficiency virus ; Isoniazid ; Lung diseases ; Macrophages ; Minimum inhibitory concentration ; Multidrug resistance ; Mycobacterium tuberculosis ; Natural products ; Oils & fats ; Pharmaceutical sciences ; Potash ; Potassium ; Pyrazinamide ; Rifampin ; Tuberculosis ; Vero cells</subject><ispartof>Future microbiology, 2019-03, Vol.14 (4), p.331-344</ispartof><rights>Copyright Future Medicine Ltd Mar 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c321t-54c27a618a7953de8925caca49fc5a88081e77a8fe580b07cfd5bae5d3322a1c3</citedby><cites>FETCH-LOGICAL-c321t-54c27a618a7953de8925caca49fc5a88081e77a8fe580b07cfd5bae5d3322a1c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30757916$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Almeida, Aryadne L</creatorcontrib><creatorcontrib>Caleffi-Ferracioli, Katiany R</creatorcontrib><creatorcontrib>de L Scodro, Regiane B</creatorcontrib><creatorcontrib>Baldin, Vanessa P</creatorcontrib><creatorcontrib>Montaholi, Débora C</creatorcontrib><creatorcontrib>Spricigo, Luiza F</creatorcontrib><creatorcontrib>Nakamura-Vasconcelos, Sandra S</creatorcontrib><creatorcontrib>Hegeto, Laíse A</creatorcontrib><creatorcontrib>Sampiron, Eloísa G</creatorcontrib><creatorcontrib>Costacurta, Giovana F</creatorcontrib><creatorcontrib>Dos S Yamazaki, Diego A</creatorcontrib><creatorcontrib>F Gauze, Gisele de</creatorcontrib><creatorcontrib>Siqueira, Vera Ld</creatorcontrib><creatorcontrib>Cardoso, Rosilene F</creatorcontrib><title>Eugenol and derivatives activity against Mycobacterium tuberculosis, nontuberculous mycobacteria and other bacteria</title><title>Future microbiology</title><addtitle>Future Microbiol</addtitle><description>To evaluate (i) the in vitro activity of eugenol (EUG) and three derivatives against Mycobacterium tuberculosis (Mtb), nontuberculous mycobacteria (NTM) and other bacteria, (ii) the EUG and antituberculosis drugs combinatory effect and (iii) the EUG and its derivatives cytotoxicity.
Minimum inhibitory concentration of the compounds were determined by resazurin microtiter or broth microdilution assay and the drug interaction between EUG and antituberculosis drugs by resazurin drug combination microtiter. The cytotoxicity was carried out in macrophages, HeLa and VERO cells. Results: EUG and derivatives displayed activity and synergic effect of EUG combined with rifampicin, isoniazid, ethambutol, and pyrazinamide in Mtb including multidrug-resistant isolates, with more selectivity to bacillus than macrophages, HeLa and VERO cells (selective index from 0.65 to 31.4). EUG derivatives (4-allyl-2-methoxyphenyl acetate, 4-allyl-2-methoxyphenyl benzoate, and 4-allyl-2-methoxyphenyl 4-nitrobenzoate) were more active against nontuberculous mycobacteria than EUG. EUG and derivatives exhibited low activity in other Gram-positive and -negative bacteria.
EUG and its derivatives show activity against Mycobacterium spp. and synergic effect of EUG combined with antituberculosis drugs against Mtb.</description><subject>Acetic acid</subject><subject>Antimicrobial agents</subject><subject>Bacteria</subject><subject>Cytotoxicity</subject><subject>Drug interaction</subject><subject>Drug interactions</subject><subject>Drugs</subject><subject>Ethambutol</subject><subject>Eugenol</subject><subject>Gram-negative bacteria</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Isoniazid</subject><subject>Lung diseases</subject><subject>Macrophages</subject><subject>Minimum inhibitory concentration</subject><subject>Multidrug resistance</subject><subject>Mycobacterium tuberculosis</subject><subject>Natural products</subject><subject>Oils & fats</subject><subject>Pharmaceutical sciences</subject><subject>Potash</subject><subject>Potassium</subject><subject>Pyrazinamide</subject><subject>Rifampin</subject><subject>Tuberculosis</subject><subject>Vero cells</subject><issn>1746-0913</issn><issn>1746-0921</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpd0c1LwzAYBvAgipvTo1cJePFgNR9Lkx5lzA-YeNFzeZums6NtZtIM9t8vcx-Cpze8_Hh4yYPQNSUPjFH5WLVFwghVCeGcn6AhleM0IRmjp8c35QN04f2CEKFoRs_RgBMpZEbTIfLTMDedbTB0JS6Nq1fQ1yvjMeg4636NYQ5153v8vta2iNtoQov7UBinQ2N97e9xZ7vjInjc_lH4Dbb9t3H4sLpEZxU03lzt5wh9PU8_J6_J7OPlbfI0SzRntE_EWDMJKVUgM8FLozImNGgYZ5UWoBRR1EgJqjJCkYJIXZWiACNKzhkDqvkI3e1yl87-BOP7vK29Nk0DnYln5owRmXHJUxXp7T-6sMF18bqoaCqYlFJEleyUdtZ7Z6p86eoW3DqnZOtkHtvIt23k2zaiv9mnhqI15VEfvp9vANU7h_E</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>de Almeida, Aryadne L</creator><creator>Caleffi-Ferracioli, Katiany R</creator><creator>de L Scodro, Regiane B</creator><creator>Baldin, Vanessa P</creator><creator>Montaholi, Débora C</creator><creator>Spricigo, Luiza F</creator><creator>Nakamura-Vasconcelos, Sandra S</creator><creator>Hegeto, Laíse A</creator><creator>Sampiron, Eloísa G</creator><creator>Costacurta, Giovana F</creator><creator>Dos S Yamazaki, Diego A</creator><creator>F Gauze, Gisele de</creator><creator>Siqueira, Vera Ld</creator><creator>Cardoso, Rosilene F</creator><general>Future Medicine Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201903</creationdate><title>Eugenol and derivatives activity against Mycobacterium tuberculosis, nontuberculous mycobacteria and other bacteria</title><author>de Almeida, Aryadne L ; Caleffi-Ferracioli, Katiany R ; de L Scodro, Regiane B ; Baldin, Vanessa P ; Montaholi, Débora C ; Spricigo, Luiza F ; Nakamura-Vasconcelos, Sandra S ; Hegeto, Laíse A ; Sampiron, Eloísa G ; Costacurta, Giovana F ; Dos S Yamazaki, Diego A ; F Gauze, Gisele de ; Siqueira, Vera Ld ; Cardoso, Rosilene F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c321t-54c27a618a7953de8925caca49fc5a88081e77a8fe580b07cfd5bae5d3322a1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acetic acid</topic><topic>Antimicrobial agents</topic><topic>Bacteria</topic><topic>Cytotoxicity</topic><topic>Drug interaction</topic><topic>Drug interactions</topic><topic>Drugs</topic><topic>Ethambutol</topic><topic>Eugenol</topic><topic>Gram-negative bacteria</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Isoniazid</topic><topic>Lung diseases</topic><topic>Macrophages</topic><topic>Minimum inhibitory concentration</topic><topic>Multidrug resistance</topic><topic>Mycobacterium tuberculosis</topic><topic>Natural products</topic><topic>Oils & fats</topic><topic>Pharmaceutical sciences</topic><topic>Potash</topic><topic>Potassium</topic><topic>Pyrazinamide</topic><topic>Rifampin</topic><topic>Tuberculosis</topic><topic>Vero cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Almeida, Aryadne L</creatorcontrib><creatorcontrib>Caleffi-Ferracioli, Katiany R</creatorcontrib><creatorcontrib>de L Scodro, Regiane B</creatorcontrib><creatorcontrib>Baldin, Vanessa P</creatorcontrib><creatorcontrib>Montaholi, Débora C</creatorcontrib><creatorcontrib>Spricigo, Luiza F</creatorcontrib><creatorcontrib>Nakamura-Vasconcelos, Sandra S</creatorcontrib><creatorcontrib>Hegeto, Laíse A</creatorcontrib><creatorcontrib>Sampiron, Eloísa G</creatorcontrib><creatorcontrib>Costacurta, Giovana F</creatorcontrib><creatorcontrib>Dos S Yamazaki, Diego A</creatorcontrib><creatorcontrib>F Gauze, Gisele de</creatorcontrib><creatorcontrib>Siqueira, Vera Ld</creatorcontrib><creatorcontrib>Cardoso, Rosilene F</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Almeida, Aryadne L</au><au>Caleffi-Ferracioli, Katiany R</au><au>de L Scodro, Regiane B</au><au>Baldin, Vanessa P</au><au>Montaholi, Débora C</au><au>Spricigo, Luiza F</au><au>Nakamura-Vasconcelos, Sandra S</au><au>Hegeto, Laíse A</au><au>Sampiron, Eloísa G</au><au>Costacurta, Giovana F</au><au>Dos S Yamazaki, Diego A</au><au>F Gauze, Gisele de</au><au>Siqueira, Vera Ld</au><au>Cardoso, Rosilene F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Eugenol and derivatives activity against Mycobacterium tuberculosis, nontuberculous mycobacteria and other bacteria</atitle><jtitle>Future microbiology</jtitle><addtitle>Future Microbiol</addtitle><date>2019-03</date><risdate>2019</risdate><volume>14</volume><issue>4</issue><spage>331</spage><epage>344</epage><pages>331-344</pages><issn>1746-0913</issn><eissn>1746-0921</eissn><abstract>To evaluate (i) the in vitro activity of eugenol (EUG) and three derivatives against Mycobacterium tuberculosis (Mtb), nontuberculous mycobacteria (NTM) and other bacteria, (ii) the EUG and antituberculosis drugs combinatory effect and (iii) the EUG and its derivatives cytotoxicity.
Minimum inhibitory concentration of the compounds were determined by resazurin microtiter or broth microdilution assay and the drug interaction between EUG and antituberculosis drugs by resazurin drug combination microtiter. The cytotoxicity was carried out in macrophages, HeLa and VERO cells. Results: EUG and derivatives displayed activity and synergic effect of EUG combined with rifampicin, isoniazid, ethambutol, and pyrazinamide in Mtb including multidrug-resistant isolates, with more selectivity to bacillus than macrophages, HeLa and VERO cells (selective index from 0.65 to 31.4). EUG derivatives (4-allyl-2-methoxyphenyl acetate, 4-allyl-2-methoxyphenyl benzoate, and 4-allyl-2-methoxyphenyl 4-nitrobenzoate) were more active against nontuberculous mycobacteria than EUG. EUG and derivatives exhibited low activity in other Gram-positive and -negative bacteria.
EUG and its derivatives show activity against Mycobacterium spp. and synergic effect of EUG combined with antituberculosis drugs against Mtb.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>30757916</pmid><doi>10.2217/fmb-2018-0333</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1746-0913 |
| ispartof | Future microbiology, 2019-03, Vol.14 (4), p.331-344 |
| issn | 1746-0913 1746-0921 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2207937368 |
| source | PubMed Central |
| subjects | Acetic acid Antimicrobial agents Bacteria Cytotoxicity Drug interaction Drug interactions Drugs Ethambutol Eugenol Gram-negative bacteria HIV Human immunodeficiency virus Isoniazid Lung diseases Macrophages Minimum inhibitory concentration Multidrug resistance Mycobacterium tuberculosis Natural products Oils & fats Pharmaceutical sciences Potash Potassium Pyrazinamide Rifampin Tuberculosis Vero cells |
| title | Eugenol and derivatives activity against Mycobacterium tuberculosis, nontuberculous mycobacteria and other bacteria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T12%3A47%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Eugenol%20and%20derivatives%20activity%20against%20Mycobacterium%20tuberculosis,%20nontuberculous%20mycobacteria%20and%20other%20bacteria&rft.jtitle=Future%20microbiology&rft.au=de%20Almeida,%20Aryadne%20L&rft.date=2019-03&rft.volume=14&rft.issue=4&rft.spage=331&rft.epage=344&rft.pages=331-344&rft.issn=1746-0913&rft.eissn=1746-0921&rft_id=info:doi/10.2217/fmb-2018-0333&rft_dat=%3Cproquest_cross%3E2207937368%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2216527775&rft_id=info:pmid/30757916&rfr_iscdi=true |